126 26

Full metadata record

DC FieldValueLanguage
dc.contributor.author배상철-
dc.date.accessioned2019-12-03T04:26:03Z-
dc.date.available2019-12-03T04:26:03Z-
dc.date.issued2017-12-
dc.identifier.citationARTHRITIS RESEARCH & THERAPY, v. 19, Article no. 287en_US
dc.identifier.issn1478-6354-
dc.identifier.issn1478-6362-
dc.identifier.urihttps://arthritis-research.biomedcentral.com/articles/10.1186/s13075-017-1495-6-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/116769-
dc.description.abstractBackground: In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE.Methods: We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event.Results: Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P = 0.006). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety.Conclusions: Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.en_US
dc.description.sponsorshipThis work was funded by LUPUS UK, The Rosetrees Trust and Arthritis Research UK Programme Grant 19423, and was supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. Drs Ioannou and Isenberg are also supported by Arthritis Research UK Grant 20164. Dr. Hanly's work was supported by the Canadian Institutes of Health Research (research grant MOP-86526). Dr. Sang-Cheol Bae's work was in part by unrestricted grant (Hanyang University 201600000001387). Dr. Caroline Gordon's work was supported by Lupus UK, Sandwell and West Birmingham Hospitals National Health Service (NHS) Trust and the NIHR/Wellcome Trust Clinical Research Facility in Birmingham. Dr Petri and the Hopkins Lupus Cohort are supported by the National Institutes of Health (NIH) (grant AR43727). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Universite Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is an NIHR Senior Investigator and is funded by Arthritis Research UK, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Dr. Soren Jacobsen is supported by the Danish Rheumatism Association (A1028) and the Novo Nordisk Foundation (A05990). Dr. Ramsey-Goldman's work was supported by the NIH (grants 1U54TR001353 formerly 8UL1TR000150 and UL-1RR-025741, K24-AR-02318, and P60AR064464 formerly P60-AR-48098). Dr. Mary Anne Dooley's work was supported by the NIH grant RR00046. Dr. Ruiz-Irastorza is supported by the Department of Education, Universities and Research of the Basque Government. None of these funding bodies played any role in the design of the study, collection, analysis or interpretation of the data.en_US
dc.language.isoen_USen_US
dc.publisherBIOMED CENTRAL LTDen_US
dc.subjectSystemic lupus erythematosusen_US
dc.subjectNeuropsychiatricen_US
dc.subjectNucleosomesen_US
dc.subjectNitrationen_US
dc.titleNitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosusen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume19-
dc.identifier.doi10.1186/s13075-017-1495-6-
dc.relation.page1-9-
dc.relation.journalARTHRITIS RESEARCH & THERAPY-
dc.contributor.googleauthorFerreira, Isabel-
dc.contributor.googleauthorCroca, Sara-
dc.contributor.googleauthorRaimondo, Maria Gabriella-
dc.contributor.googleauthorMatharu, Manjit-
dc.contributor.googleauthorMiller, Sarah-
dc.contributor.googleauthorGiles, Ian-
dc.contributor.googleauthorIsenberg, David-
dc.contributor.googleauthorIoannou, Yiannis-
dc.contributor.googleauthorHanly, John G.-
dc.contributor.googleauthorBae, Sang-Cheol-
dc.relation.code2017002362-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidscbae-
dc.identifier.orcidhttp://orcid.org/0000-0003-4658-1093-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE